Production of non viral DNA vectors.
After some decades of research, development and first clinical approaches to use DNA vectors in gene therapy, cell therapy and DNA vaccination, the requirements for the pharmaceutical manufacturing of gene vectors has improved significantly step by step. Even the expression level and specificity of non viral DNA vectors were significantly modified and followed the success of viral vectors. The strict separation of "viral" and "non viral" gene transfer are historic borders between scientist and we will show that both fields together are able to allow the next step towards successful prevention and therapy. Here we summarize the features of producing and modifying these non-viral gene vectors to ensure the required quality to modify cells and to treat human and animals.
Plasmid Factory GmbH & Co. KG, Meisenstrasse 96, D-33739 Bielefeld, Germany. martin.schleef@plasmidfactory.com
Martin
M
Schleef
Markus
M
Blaesen
Marco
M
Schmeer
Ruth
R
Baier
Corinne
C
Marie
George
G
Dickson
Daniel
D
Scherman
D004247:DNA / Q000096:biosynthesis*; D005822:Genetic Vectors / Q000096:biosynthesis* / Q000235:genetics; D004364:Pharmaceutical Preparations / Q000737:chemistry
D004364:Pharmaceutical Preparations; D004247:DNA